-------如果这里没有任何信息，不是真没有，是我们懒！请复制书名上amazon搜索书籍信息。-------
This continuing education activity reviews best practices in the growing field of radiotheragnostics (aka theranostics or theragnostics) for benign and malignant diseases, beginning with the fundamentals and extending to include advanced clinical applications. A review of historically established therapies that have been optimally modernized as well as the recently introduced state-of-the-art modalities are included. The expert faculty discuss the optimization of the radiotheragnostic practices for best utilization of various radiopharmaceuticals in contemporary health care delivery systems, both academic and private practice settings.Target Audience This meeting is designed for nuclear medicine physicians, nuclear radiologists, oncologists, health physicists, and radiopharmacists.Educational Objectives At the completion of this CME activity, subscribers should be able to:- The difference between the radiotheragnostic approach and various other concepts guiding the therapeutic delivery of radiation to the target tissues with the objective of improving health outcomes.- The best therapeutic practice approaches to hyperthyroidism and other benign thyroid diseases, based on evidence and/or sound medical judgment.- The best therapeutic practice approaches to differentiated thyroid carcinoma, based on evidence and/or sound medical judgment.- The optimal applications of Y-90 Ibritumomab Tiuxetan for therapy of lymphoma.- The optimal applications of I-131 Iobenguane to diagnostic imaging and therapy of Pheochromocytoma and Paraganglioma.- The optimal applications of Y-90 Resin and Glass Microspheres to radioembolization therapy of liver cancers.- The optimal applications of Ga-68 Dotatate Imaging and Lu-177 Dotatate therapy of neuroendocrine tumors.- The optimal approach to diagnostic imaging of recurrent and metastatic prostate cancer.- The best approach to therapy of skeletal metastatic disease using various Bone-Seeking radiopharmaceuticals.- The practical examples for evaluation of not listed cancers for radiotheragnostics-based trials.- Best approaches to building radiotheragnostic practice in academic institutions.- Best approaches to building radiotheragnostic practice in private practice settings.Topics/Speakers : History & Practice of Radioiodine Therapy in HyperthyroidismMark Tulchinsky, M.D., FACNM, FSNMMI, CCDOverview of Targeted Therapy - Lessons LearnedTerence Z. Wong, M.D., Ph.D.Radioiodine Therapy: Uncommon Benign Thyroid ConditionsMark Tulchinsky, M.D., FACNM, FSNMMI, CCDI-131 Iobenguane Imaging & Therapy for Pheochromocytoma/ParagangliomaErik S. Mittra M.D., Ph.D.Radioiodine in Thyroid Cancer - BasicsMark Tulchinsky, M.D., FACNM, FSNMMI, CCDRadioiodine in Thyroid Cancer - AdvancedMark Tulchinsky, M.D., FACNM, FSNMMI, CCDRadioembolization Therapy with Y-90 Resin and Glass MicrospheresTerence Z. Wong, M.D., Ph.D.Ga-68/Lu-177 Dotatate Imaging/Therapy of Neuroendocrine TumorsErik S. Mittra M.D., Ph.D.Diagnostic Imaging of Recurrent and Metastatic Prostate CancerSamuel Mehr, M.D.Therapy for Skeletal Metastatic Disease with Bone-Seeking AgentsTerence Z. Wong, M.D., Ph.D.Radiotheragnostics in Prostate CancerTerence Z. Wong, M.D., Ph.D.Pivotal Trials in the USA for Up-and-Coming RadiotheragnosticsErik S. Mittra M.D., Ph.D.Opportunities for Somatostatin Receptor Targeting in Avid CancersSamuel Mehr, M.D.Building Nuclear Medicine Therapy Program in Academic PracticeErik S. Mittra M.D., Ph.D.Building Nuclear Medicine Therapy Program in Private PracticeSamuel Mehr, M.D.CME Release Date 2/14/2021CME Expiration Date 2/14/2024
